Brief: Gufic Biosciences Received Approval From National Medical Products Administration, China For Product Prilocaine (API)
16/06/2023 13:21
June 16 (Reuters) - Gufic Biosciences Ltd GUFI.NS :
* RECEIVED APPROVAL FROM NATIONAL MEDICAL PRODUCTS
ADMINISTRATION, CHINA FOR PRODUCT PRILOCAINE (API)
Source text for Eikon: ID:
Further company coverage: GUFI.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gufic Biosciences
See all newsBrief: Gufic Biosciences Says USFDA Pre-Approval Inspection At Indore Facility
Brief: Gufic Biosciences June-Quarter Consol Total Profit 223.1 Million Rupees
Brief: Gufic Biosciences Receives Tax Demand Notice For 43.3 Million Rupees
Brief: Gufic Biosciences Receives Tax Demand Notice For 43.3 Million Rupees
Brief: Gufic Biosciences posts Sept-Quarter Consol Revenue From Operations 2.37 Billion Rupees